NASDAQ:ALKS - Nasdaq - IE00B56GVS15 - Common Stock - Currency: USD
ALKS gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 556 industry peers in the Biotechnology industry. ALKS has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. ALKS scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings could make ALKS a good candidate for value investing.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 16.91% | ||
ROE | 23.28% | ||
ROIC | 20.05% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 25.9% | ||
PM (TTM) | 23.25% | ||
GM | 84.42% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | 0 | ||
Altman-Z | 5.84 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 3.33 | ||
Quick Ratio | 2.92 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 9.54 | ||
Fwd PE | 14.21 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 8.93 | ||
EV/EBITDA | 7 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
26.13
-0.4 (-1.51%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 9.54 | ||
Fwd PE | 14.21 | ||
P/S | 2.85 | ||
P/FCF | 8.93 | ||
P/OCF | 8.33 | ||
P/B | 2.85 | ||
P/tB | 3.02 | ||
EV/EBITDA | 7 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 16.91% | ||
ROE | 23.28% | ||
ROCE | 23.93% | ||
ROIC | 20.05% | ||
ROICexc | 43.56% | ||
ROICexgc | 49.02% | ||
OM | 25.9% | ||
PM (TTM) | 23.25% | ||
GM | 84.42% | ||
FCFM | 31.86% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | 0 | ||
Debt/EBITDA | 0 | ||
Cap/Depr | 122.21% | ||
Cap/Sales | 2.29% | ||
Interest Coverage | 250 | ||
Cash Conversion | 122.99% | ||
Profit Quality | 137.03% | ||
Current Ratio | 3.33 | ||
Quick Ratio | 2.92 | ||
Altman-Z | 5.84 |